NCT01222598已完成不适用
Minirin Melt Tolerance With Nocturia in the Common Practice Conditions in Czech Republic
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 588
- 试验地点
- 28
- 主要终点
- Number of participants with adverse events
研究概览
简要总结
This is a confirmation of safety profile for Minirin Melt in clinical practice.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients suffering from Nocturia
排除标准
- •habitual or psychogenic polydipsia
- •known or suspected cardiac insufficiency and other conditions requiring treatment with diuretics
- •moderate and severe renal insufficiency
- •know hyponatremia
- •syndrome of inappropriate ADH secretion
结局指标
主要结局
Number of participants with adverse events
时间窗: 12 months
次要结局
- Number of participants with nocturnal voiding(12 months)
- Number of participants with adverse events(12 months)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
不适用
A Study of Minirin Melt in 24 Months Treatment in Patients With NocturiaNocturiaNCT01552395Ferring Pharmaceuticals4,136
已完成
不适用
A Study of Minirin Melt in Patients With NocturiaNocturiaNCT01212224Ferring Pharmaceuticals2,187
终止
不适用
Study of Minirin Melt® in Adult Patients With NocturiaNocturiaNCT03089073Ferring Pharmaceuticals835
已完成
不适用
Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced VasospasmCerebral VasospasmSubarachnoid HemorrhageNCT03517670Nantes University Hospital60
终止
不适用
Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the NewbornPersistent Fetal Circulation SyndromeNCT01088997Children's Hospital of Philadelphia12